2019-11-12T16:39:05-06:00 2018-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2018-01-01 943384500 PATH DRUG SOLUTIONS PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 BRIAN NEVILLE CHIEF OF ACCOUNTING 2062853500 2019-11-12 1 RICHARD J LOCASTRO CPA P00288314 3019519090 75.103.231.202 2019-11-12 17:38:52 ES P 4FA38BE9C690C82C721A5060F87FC7588CB81F81 60F5620986AF14763908AFE7AC6F4ECEC523E148 2018 2020-04-17 16:48:07Z X BRIAN NEVILLE 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 2972163 0 X WWW.PATH.ORG X 2000 CA SEE PART III, LINE 1. X 8 3 0 0 0 0 146405 2830607 0 0 53741 141556 1000 0 201146 2972163 2009027 3194525 0 0 0 0 0 0 0 539152 381678 2548179 3576203 -2347033 -604040 7105262 0 708783 0 6396479 0 X THE MISSION OF PATH DRUG SOLUTIONS (PDS) IS TO DEVELOP AND ADVANCE SAFE AND EFFECTIVE MEDICINES FOR THE PREVENTION AND TREATMENT OF DISEASES DISPROPORTIONATELY AFFECTING WOMEN AND CHILDREN IN LOW-RESOURCE SETTINGS. WE WORK WITH A VARIETY OF PUBLIC- AND PRIVATE-SECTOR STAKEHOLDERS TO BUILD CROSS-SECTOR COLLABORATIONS, SECURE INTELLECTUAL PROPERTY, REVISIT PROMISING DRUGS OR DRUG CANDIDATES THAT HAVE BEEN SET ASIDE FOR NONMEDICAL REASONS (E.G., LACK OF EARNING POTENTIAL), AND HARNESS SCIENTIFIC AND MANUFACTURING CAPACITY IN COUNTRIES AROUND THE WORLD TO ENSURE THAT DRUGS ARE AVAILABLE, ACCESSIBLE, AFFORDABLE, AND ACCEPTABLE AND THAT SUPPLIES ARE SUSTAINABLE TO ALL THOSE WHO NEED THEM. 0 1 3542988 3194525 IN NOVEMBER 2017, THE PDS BOARD DISCUSSED DISSOLUTION PDS. IN 2018, A NUMBER OF ACTIVITIES WERE CARRIED OUT TO COMPLETE THE DISSOLUTION PROCESS, INCLUDING PRODUCT PATENT TRANSFERS FROM PDS TO PATH, ENGAGEMENT OF LEGAL COUNSEL FOR DISSOLUTION PROCEDURES, AND OTHER ADMINISTRATIVE WORK. ON DECEMBER 31, 2018, THE DISSOLUTION OF PDS WAS FORMALLY RECOGNIZED BY THE CALIFORNIA SECRETARY OF STATE.IN JANUARY 2018, FOLLOWING THE CONCLUSION OF THE PHASE 2 CLINICAL STUDY OF RILPIVIRINE LA, A LONG-ACTING INJECTABLE DRUG TO PREVENT INFECTION WITH HIV WHEN USED BEFORE EXPOSURE, PDS COMPLETED ALL REMAINING STUDY CLOSE-OUT ACTIVITIES. THE INVESTIGATIONAL NEW DRUG APPLICATION FOR RILPIVIRINE LA HAS BEEN PLACED IN AN INACTIVE STATUS WITH THE US FOOD AND DRUG ADMINISTRATION, AND THE PROJECT IS NOW FINISHED.IN 2018, PDS CONTINUED WORK TO REDUCE THE BURDEN OF VISCERAL LEISHMANIASIS, ALSO KNOWN AS KALA-AZAR. KALA-AZAR IS A PARASITIC DISEASE COMMON IN AFRICA AND ASIA AND IS ALMOST ALWAYS FATAL IF LEFT UNTREATED. PDS SUPPORTED THE GOVERNMENT OF NEPAL IN ACTIVE CASE DETECTION USING BOTH A CAMP-BASED APPROACH AND AN INDEX CASE-BASED APPROACH IN KALA-AZAR ENDEMIC DISTRICTS. PDS ALSO HOSTED AN INTERNATIONAL POST-KALA-AZAR DERMAL LEISHMANIASIS (PKDL) CONSORTIUM MEETING TO PROVIDE GUIDANCE ON IMPROVING DIAGNOSIS, TREATMENT, AND FOLLOW-UP OF PKDL CASES.TO BUILD CLINICAL RESEARCH CAPACITY IN INDIA, PDS WORKED TO FURTHER DEVELOP AND IMPLEMENT A CLINICAL RESEARCH TRAINING AND MENTORSHIP PROGRAM. THIS WORK WAS DONE IN COLLABORATION WITH THREE NATIONAL CLINICAL RESEARCH RESOURCE CENTERS SPECIALIZING IN PHARMACOVIGILANCE, RESEARCH ETHICS, AND DATA MANAGEMENT. 3542988 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 1 0 0 0 0 1 IN 0 0 0 0 0 0 0 0 0 0 X 8 3 0 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 CA WA X X BRIAN NEVILLE CHIEF OF ACCOUNTING 2062853500 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 STEPHEN B DAVIS BOARD CHAIR & PRESIDENT 1.00 39.00 X X 0 665877 62780 OLIVIA D POLIUS TREASURER & CFO 1.00 39.00 X X 0 320646 51936 DANIEL LASTER SECRETARY 1.00 39.00 X X 0 310669 41544 DAVID C KASLOW DIRECTOR 1.00 39.00 X 0 379045 65678 JORGE FLORES DIRECTOR 1.00 39.00 X 0 307792 43046 KEITH CHIRGWIN DIRECTOR 2.00 0.00 X 0 0 0 KEN DUNCAN DIRECTOR 2.00 0.00 X 0 0 0 DAN HARTMAN DIRECTOR 2.00 0.00 X 0 0 0 0 1984029 264984 0 0 1 0 0 2830607 2830607 141556 141556 2972163 0 0 141556 2964636 2964636 229889 229889 20559 20559 101747 101747 49 49 13336 13336 1839 1839 97 97 115031 115031 12983 12983 582 582 SUBCONTRACTS 74268 74268 EQUIPMENT R&M 5633 5633 STORAGE 2112 2112 MEMBERSHIP DUES 809 809 32633 32633 3576203 3542988 33215 0 105262 0 7000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7105262 0 708783 708783 0 X 558860 0 5837619 0 6396479 0 7105262 0 X -604040 -5792439 X 0 1 X 1 0 X X 1 PATH 911157127 7 1 3576203 0 1 3576203 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 91 EUROPE 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 4911 EUROPE 0 0 GRANTMAKING 73000 SOUTH ASIA 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 155581 SOUTH ASIA 0 0 GRANTMAKING 156889 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 293 0 0 0 0 0 0 390765 0 390765 EUROPE GLOBAL HEALTH PROGRAM 73000 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAM 21216 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAM 28396 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAM 100249 CHECK/WIRE 4 0 1 0 0 0 0 0 PART I, LINE 2: PDS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE TO GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PDS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND THAT IT ACHIEVES PERFORMANCE GOALS. 1 PATH 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 2964636 GENERAL SUPPORT 1 0 PART I, LINE 2: PDS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE TO GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PDS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND THAT IT ACHIEVES PERFORMANCE GOALS. 0 0 0 0 0 0 0 0 0 STEPHEN B DAVIS BOARD CHAIR & PRESIDENT 0 512010 0 152067 0 1800 0 32200 0 30580 0 728657 0 0 OLIVIA D POLIUS TREASURER & CFO 0 318546 0 0 0 2100 0 32400 0 19536 0 372582 0 0 DANIEL LASTER SECRETARY 0 308869 0 0 0 1800 0 32400 0 9144 0 352213 0 0 DAVID C KASLOW DIRECTOR 0 377245 0 0 0 1800 0 32400 0 33278 0 444723 0 0 JORGE FLORES DIRECTOR 0 307792 0 0 0 0 0 32400 0 10646 0 350838 0 0 PART I, LINE 3 PDS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING TO ESTABLISH COMPENSATION OF THE EXECUTIVE DIRECTOR: - COMPENSATION COMMITTEE - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE CASH 2018-12-19 1521220 ACUTAL 911157127 PATH 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 501(C)(3) 1 1 0 0 1 1 1 1 0 PART I, LINE 2E: PERSON(S) INVOLVED: PATH DRUG SOLUTIONS (PDS) WAS A SUPPORTING ORGANIZATION TO PATH. VARIOUS PDS BOARD MEMBERS ARE ALSO EMPLOYEES AND/OR BOARD MEMBERS OF PATH. FORM 990, PART III, LINE 3 PDS DISOLVED EFFECTIVE DECEMBER 31, 2018 AND CEASED CONDUCTING ACTIVITIES. FORM 990, PART VI, SECTION A, LINE 4 IN ACCORDANCE WITH THE NOVEMBER 21, 2017, PDS BOARD OF DIRECTORS RESOLUTION TO WIND UP AND DISSOLVE PDS, PDS RECEIVED THE STATE OF CALIFORNIA ATTORNEY GENERAL'S WAIVER OF OBJECTION TO THE DISPOSITION OF ASSETS UPON DISSOLUTION OF PDS ON NOVEMBER 20, 2018. THE CALIFORNIA SECRETARY OF STATE SUBSEQUENTLY ACCEPTED THE CERTIFICATE OF DISSOLUTION FOR PDS ON DECEMBER 31, 2018. AFTER ALL OF PDS' KNOWN DEBTS AND LIABILITIES WERE PAID OR ADEQUATELY PROVIDED FOR, THE REMAINING CORPORATE ASSETS OF PDS WERE TRANSFERRED TO PATH IN ACCORDANCE WITH PDS' ARTICLES OF INCORPORATION AND THE ASSET TRANSFER AGREEMENT EXECUTED BY PATH AND PDS AND ACCEPTED BY THE CALIFORNIA ATTORNEY GENERAL AND SECRETARY OF STATE. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM (GELMAN, ROSENBERG & FREEDMAN, CPAS) USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO PATH'S BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CHIEF FINANCIAL OFFICER SIGNED THE FORM. FORM 990, PART VI, SECTION B, LINE 12C PDS HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PDS BOARD MEMBERS AND OFFICERS MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. PDS DOES NOT HAVE EMPLOYEES. PDS IS A SUPPORTING ORGANIZATION TO PATH WITHIN THE MEANING OF INTERNAL REVENUE CODE SECTION 509(A)(3), AND PDS CONTRACTS WITH PATH FOR MANAGEMENT SERVICES. PATH HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PATH BOARD MEMBERS, OFFICERS, AND STAFF AT HIGHER THAN A DESIGNATED LEVEL MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL PDS AND PATH DISCLOSURE FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. FORM 990, PART VI, SECTION C, LINE 19 PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. FORM 990, PART XI, LINE 9: FOR THE YEAR ENDED DECEMBER 31, 2018, THE ORGANIZATION ADOPTED THE FINANCIAL ACCOUNTING STANDARDS BOARD'S ACCOUNTING STANDARDS UPDATE (ASU) NO. 2018-08 - NOT-FOR-PROFIT ENTITIES (TOPIC 958): CLARIFYING THE SCOPE AND THE ACCOUNTING GUIDANCE FOR CONTRIBUTIONS RECEIVED AND CONTRIBUTIONS MADE FOR REVENUE TRANSACTIONS. THE UPDATE ASSISTS ENTITIES IN (1) EVALUATING WHETHER TRANSACTIONS SHOULD BE ACCOUNTED FOR AS CONTRIBUTIONS (NONRECIPROCAL TRANSACTIONS) OR AS EXCHANGE (RECIPROCAL) TRANSACTIONS AND (2) DETERMINING WHETHER A CONTRIBUTION IS CONDITIONAL. THE PRIMARY EFFECT OF ADOPTION OF THIS ASU FOR THE ORGANIZATION IS THAT CERTAIN AWARDS RECEIVED THAT WERE PREVIOUSLY TREATED AS UNCONDITIONAL ARE NOW TREATED AS CONDITIONAL. AS A RESULT, REVENUE FOR THESE AWARDS IS RECOGNIZED WHEN THE CONDITIONS ARE MET DURING THE AWARD TERM, WHEREAS PREVIOUSLY REVENUE HAD BEEN RECOGNIZED WHEN THE AWARDS WERE AWARDED. PATH HAS ELECTED TO ADOPT THE CHANGES FROM THIS ASU RETROSPECTIVELY TO THE 2017 FINANCIAL STATEMENTS. THE NET EFFECT OF THIS CHANGE IS PRESENTED AS AN OTHER CHANGE IN NET ASSETS. -5,792,439. PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 PATH VACCINE SOLUTIONS 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 830431851 ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN WA 501(C)(3) LINE 12A, I PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ 501(C)(3) PATH 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0